Yesterday afternoon, Adamis (ADMP) announced FDA approval of its lower dose version (0.15mg) of Symjepi for treatment of anaphylaxis in pediatric patients.
It’s a big day for Adamis Pharma (NASDAQ:ADMP). The drug maker announced a commercial partnership for its generic EpiPe Symjepi with Novartis (NYSE:NVS) subsidiary Sandoz, …
Now that ADMP has submitted a PAS for its pediatric version of Symjepi, an epipnephrine injection cheaper than Mylan’s EpiPen, FBR’s Andrew D’silva sees a potential approval with less risk than the original version.
